Back to PathoKing

Phaeochromocytoma module

Phaeochromocytoma

Trace catecholamine-secreting chromaffin tumours through episodic vasoconstriction, tachycardia, metabolic stress, crisis, biochemical diagnosis, alpha blockade, and surgery.

advanced32 min

Clinically reviewed by Mark · NMC-registered nurse

Aetiology

What starts Phaeochromocytoma?

Different triggers converge on the condition's central pathological process.

Sporadic adrenal tumour

Typical setting: A single adrenal chromaffin clone develops without an identified germline variant.

Autonomous catecholamine synthesis and release produces receptor-mediated systemic effects.

RET and MEN2

Typical setting: Activating RET variants predispose to adrenal tumours with medullary thyroid and parathyroid disease.

Bilateral or multifocal disease can occur, changing screening and operative planning.

VHL-related disease

Typical setting: Loss of oxygen-sensing tumour suppression promotes chromaffin neoplasia.

A noradrenergic biochemical pattern and associated renal, retinal, or CNS tumours may occur.

SDH-related paraganglioma

Typical setting: Succinate dehydrogenase dysfunction creates pseudohypoxic signalling.

Extra-adrenal, multifocal, head-and-neck, or metastatic tumours are particularly relevant.

Drug or procedural provocation

Typical setting: Anaesthesia, tumour manipulation, glucocorticoids, sympathomimetics, or inappropriate beta blockade can trigger release.

Sudden receptor stimulation produces hypertensive or haemodynamic crisis.

Mechanism chain

Cause and effect

Follow each link and use it to predict the next clinical consequence.

1

Tumour synthesises catecholamines

Chromaffin enzyme activity generates excessive vasoactive amines.

2

Release is tonic or episodic

Spontaneous secretion or triggers deliver abrupt circulating peaks.

Checking account access...